Making the Future of Nanomedicine
The EU-funded B-SMART project, set up to treat several neuro degenerative diseases, has taken a major step towards this goal by selecting a platform to manufacture its nanomedicines. Precision Nano System’s Nano Assemblr ™ will utilize RNA-based therapy to contain proteins that cause pathologies such as Parkinson’s Alzheimer’s and Huntington’s chorea. These diseases affect more than seven million Europeans, the load inherent socioeconomic having been estimated.
Overcoming the Barrier of RNA Therapy
RNA is an influential molecule in the coding decoding, regulation and expression of genes, including the production of the proteins responsible for the disease. The prospect of using set this function (via messenger RNA mRNA) that the drug can give the instruction to the body to prevent damage before they happen has been well received. This is a relatively new medical field, which is only about 20 years old and is considered safer and more cost-effective than alternative genetic engineering options.
However, RNA for these modalities realize all their potential, they must overcome the body’s defenses, developed over billions of years of evolution. Protections such as lipid bilayers forming a thin membrane whose role was to prevent access to the interior of the cells, kept the RNAs outside the cells. Crossing this shield was literally an obstacle to the large-scale development of RNA therapy.
B-SMART has developed a highly effective delivery mechanism with nano. These transport modules are small enough to cross the cerebrospinal fluid barrier of the brain while protecting the RNA enzymes from degradation. As the B-SMART project coordinator Professor Raymond Schiffelers, summarized in a recent article for Technology Networks announcing the selection of the manufacturing platform. RNA-based drugs are interesting because you can use exactly the same same polynucleotide molecule to treat many diseases just by changing the sequence of the nucleotide. Our target is to develop modular nanoparticles capable of delivering a payload of therapeutic RNA in the brain.
From lab to clinic
To increase efficiency the delivery mechanism required specific targeting using ligands small molecules ions or proteins based on heavy chain nanocorps only, which are smaller and more stable than conventional antibodies. The modular delivery system is tested in vitro and in vivo.
Leveraging the knowledge gathered forms the multidisciplinary field of microfluidics and the development of an evolutionary. Reproducible manufacturing process is the key to commercializing the B-SMART approach and applying it to a wide range of European therapeutic environments.http://www.thetechnologylounge.com/making-the-future-of-nanomedicine/Health Technologymedical nanotechnology,nanomaterials,nanotechnology and medicine